Targeted lung cancer drugs shrink tumors caused by rare mutations - STAT

Targeted lung cancer drugs shrink tumors caused by rare mutations - STAT

STAT Plus: At ASCO, targeted lung cancer drugs shrink tumors caused by rare genetic mutations

By ADAM FEUERSTEIN

ANNE WESTON/FRANCIS CRICK INSTITUTE/WELLCOME

Two drugs in clinical trials — from Blueprint Medicines and Takeda — are shrinking tumors in patients not helped by current treatments.

READ MORE